Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- presença de fatores de risco
- doença recorrente
- resposta insatisfatória à antibioticoterapia prévia
- comedões abertos nas áreas intertriginosas (axila, virilha, períneo ou região inframamária)
- nódulos ou abscesso
- distribuição simétrica
- tratos sinusais com cicatrização
Otros factores de diagnóstico
- piora pré-menstrual
Factores de riesgo
- obesidade
- sexo feminino
- tabagismo
- história familiar positiva
- Afro-americanos
Pruebas diagnósticas
Pruebas diagnósticas que deben considerarse
- cultura bacteriana
- biópsia de pele
Algoritmo de tratamiento
abscesso agudo
leve (estágio I de Hurley)
moderada (estágio II de Hurley)
grave (estágio III de Hurley)
Colaboradores
Autores
David Cassarino, MD, PhD
Consultant Dermatopathologist
Southern California Permanente Medical Group
Los Angeles Medical Center
Los Angeles
CA
Disclosures
DC declares that he has no competing interests.
Acknowledgements
Dr David Cassarino would like to gratefully acknowledge Dr Robert A. Lee, the previous contributor to this topic.
RAL declares that he has no competing interests.
Peer reviewers
David R. Adams, MD, PharmD
Associate Professor of Dermatology
Penn State Hershey Medical Center
Hershey
PA
Disclosures
DRA declares that he has no competing interests.
Ravi Ubriani, MD, FAAD
Assistant Professor of Clinical Dermatology
Columbia University
New York
NY
Disclosures
RU declares that he has no competing interests.
Andrew Carmichael, MB, BS
Consultant Dermatologist
James Cook University Hospital
Middlesbrough
UK
Disclosures
AC declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Kim WB, Sibbald RG, Hu H, et al. Clinical features and patient outcomes of hidradenitis suppurativa: a cross-sectional retrospective study. J Cutan Med Surg. 2016;20:52-57.Full text Abstract
Martorell A, García-Martínez FJ, Jiménez-Gallo D, et al. An update on hidradenitis suppurativa (part I): epidemiology, clinical aspects, and definition of disease severity. Actas Dermosifiliogr. 2015;106:703-715.Full text Abstract
Sabat R, Jemec GBE, Matusiak Ł, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020 Mar 12;6(1):18. Abstract
Martorell A, García FJ, Jiménez-Gallo D, et al. Update on hidradenitis suppurativa (part II): treatment. Actas Dermosifiliogr. 2015;106:716-724.Full text Abstract
Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422-34.Full text Abstract
Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev. 2015;(10):CD010081.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Acne vulgar
- Doença de Crohn
- Psoríase inversa
More DifferentialsGuidelines
- North American clinical management guidelines for hidradenitis suppurativa part II: Topical, intralesional, and systemic medical management
- Guidelines for the management of hidradenitis suppurativa (acne inversa)
More Guidelines
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer